2013年8月20日讯 /生物谷BIOON/ --强生（JNJ）8月19日宣布，已完成对Aragon制药的收购。该公司是一家私营药品研发公司，业务主要集中在激素诱发的癌症领域。

此次收购，囊括了Aragon制药雄激素受体拮抗剂项目，包括前列腺癌主导候选药物ARN-509，该项目的开发将由强生旗下杨森（Jassen）研发单元接管。

ARN-509是第二代雄激素受体信号抑制剂，目前正处于II期临床开发，如果获批，将能够满足更广泛的前列腺癌患者的需求。

此次收购耗资10亿美元，包括6.5亿预付款项，及3.5亿美元的履约款。（生物谷Bioon.com）

英文原文：Johnson & Johnson Completes Acquisition Of Aragon Pharmaceuticals, Inc.

Late-Stage Prostate Cancer Treatment Strengthens Oncology Pipeline

NEW BRUNSWICK, N.J., Aug. 19, 2013 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced it has successfully completed its acquisition of Aragon Pharmaceuticals, Inc., a privately-held pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancers.  Development of compounds from Aragon's androgen receptor antagonist program, including its lead androgen receptor signaling inhibitor, ARN-509, will be managed by Janssen Research & Development, LLC.

"The acquisition strengthens our prostate cancer pipeline with a second-generation, potentially best-in-class compound," said Peter F. Lebowitz, M.D., Ph.D., Global Therapeutic Area Head, Oncology. "It builds on our existing leadership position with ZYTIGA? (abiraterone acetate), and, if approved, we are hopeful ARN-509 will allow us to meet the needs of an even broader range of prostate cancer patients."

About Johnson & Johnson

Caring for the world, one person at a time…inspires and unites the people of Johnson & Johnson. We embrace research and science—bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 128,000 employees at more than 275 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.